Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Mazdutide

Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity

Innovent · Phase 3 · Recruiting · Enrollment 336

NCT07469800

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
IBI362 treatment Groupn/rn/rn/rn/r
Placebo Control Groupn/rn/rn/rn/r

Not shown

  • IBI362 treatment Group: endpoint not reported
  • Placebo Control Group: endpoint not reported